Form 4: Cytosorbents Director Exercises Subscription Rights, Acquires Shares and Warrants

Michael G. Bator, a director at Cytosorbents Corp, exercised subscription rights to acquire common stock and warrants.

Summary

• On January 17, 2025, Cytosorbents director Michael G. Bator exercised subscription rights from a rights offering.
• This resulted in the acquisition of 15,879 shares of common stock at $1.00 per share.
• Bator also received Series A and Series B warrants to purchase additional shares.
• The Series A warrants have an exercise price between $1.00 and $2.00, expiring 45 days after the closing date of the rights offering.
• The Series B warrants have an exercise price between $2.00 and $4.00, expiring 90 days after the closing date of the rights offering.
• The rights offering closed on January 10, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a director's participation in a rights offering, indicating confidence in the company. However, the potential dilution from warrants is a minor concern.

Positives

• The director's participation in the rights offering demonstrates confidence in the company.
• The exercise of rights resulted in the company receiving $15,879 in capital.

Risks

• The warrants could potentially dilute existing shareholders if exercised.
• The exercise price of the warrants is dependent on the 5-day volume weighted average price of the stock, which could fluctuate.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the biotech industry. It reflects a director's participation in a rights offering, a common method for companies to raise capital.

Comparison to Industry Standards

• Rights offerings are a common method for biotech companies to raise capital, especially when they are in the development stage.
• The terms of the warrants, with exercise prices tied to the stock's volume-weighted average price, are fairly standard in such offerings.
• Comparable companies often use similar mechanisms to raise funds and incentivize participation from existing shareholders and insiders.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised.
• The company has received $15,879 in capital from the director's participation in the rights offering.

Key Dates

Keywords

Cytosorbents, Director, Subscription Rights, Warrants, Common Stock, Rights Offering, Michael G. Bator